Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

49.62 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Here are the top movers in Tuesday's session.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Dow Tumbles Over 1%; Nio Shares Edge Lower After Q2 Results
 
Via Benzinga
Topics Stocks
Retail Buzz Soars As Cytokinetics Jumps 34% In Europe On Heart Drug Breakthrough
Via Stocktwits
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Earnings Scheduled For May 6, 2025
 
Via Benzinga
Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session.
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
Cytokinetics (CYTK) Stock Is Skyrocketing Tuesday: What's Driving The Action?
Shares of Cytokinetics are trading sharply higher Tuesday. The company presented new long-term safety and efficacy data for its investigational drug, aficamten. 
Via Benzinga
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Tuesday's pre-market session: top gainers and losers
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Cytokinetics And The 'Provocative Conversation' That Could Rewrite Heart Disease
Cytokinetics said Saturday its experimental treatment for a progressive heart disease outperformed standard beta blockers. 
Via Investor's Business Daily
Tesla Stock 'Could Fall 90% Tomorrow,' Fund Manager Still Won't Buy — Here's Where He's Investing Instead
A fund manager who beats 99% of his peers calls Tesla stock overvalued. Here's a look at some of his preferred investments. 
Via Benzinga
CYTK Earnings Jump 3,065%
Via The Motley Fool
Topics Economy Intellectual Property
FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months
FDA extended the aficamten decision deadline to Dec. 26 after classifying the REMS submission as a major amendment to the NDA review. 
Via Benzinga
Block, Atlassian, Apple, Roku, Amazon And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
Get insights into the top gainers and losers of Thursday's after-hours session.
The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday
 
Via Benzinga
Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach
FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use 
Via Benzinga
Which stocks are moving after the closing bell on Wednesday?
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Why Is US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday?
Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new safety concerns. 
Via Benzinga
Applied Digital Posts Weak Revenue, Joins Allegro MicroSystems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It
The companies are facing off with their heart drugs in a growing disease area. 
Via Investor's Business Daily
Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged
Edgewise Therapeutics stock dropped, as Cytokinetics shares got a big boost early Wednesday. 
Via Investor's Business Daily
Topics Bankruptcy
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.